Clinical Biomarkers - A Global and Regional Analysis

Focus on Offering, Clinical Area, Technology, Application, End User, and Region - Analysis and Forecast, 2022-2032

Published Year:
SKU:BHP0826SB

$5250

Online Access for 1-3 Users. Permission to Print.


In case you require a hard copy, there will be an additional charge of $500. Please email us at [email protected] with your request.

A quick peek into the report

Market Report Coverage

Clinical Biomarkers Market
Forecast Period: 2022-2032
CAGR During Forecast Period: 8.73%

Clinical Biomarkers Market

Base Year

2021

Market Size in 2021

$21,304.3 Million

Forecast Period

2022-2032

Value Projection and Estimation by 2032

$54,294.0 Million

CAGR During Forecast Period

8.73%

Number of Tables

20

Number of Pages

254

Number of Figures

209

 

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

•    Abbott.
•    Agilent Technologies, Inc.
•    Bio-Rad Laboratories, Inc.
•    Illumina, Inc.
•    PerkinElmer Inc.
•    QIAGEN N.V.
•    Thermo Fisher Scientific Inc.
•    NeoGenomics Laboratories
•    Charles River Laboratories
•    F. Hoffmann-La Roche Ltd
•    Quest Diagnostics Incorporated
•    Enzo Biochem Inc.
•    ALCEN
•    Myriad Genetics, Inc.
•    CENTOGENE N.V.
•    bioMérieux S.A.
•    Arsenal Capital Partners
•    Novogene Co., Ltd.
•    Q2 Solutions
•    Caris Life Sciences
•    Broad Institute
•    Personalis Inc.
•    Azenta Life Sciences
•    Discovery Life Sciences(DLS)
•    BGI
•    Eurofins Scientific
•    Becton, Dickinson and Company

How can this report add value to an organization?

Several companies, including Thermo Fisher Scientific Inc. and QIAGEN N.V., were involved in product innovations.

Product/Innovation Strategy:  Product launches and upgrades in the clinical biomarkers industry are aimed at advancing the overall technologies in the market to ensure efficient detection of various applications such as forensic and paternity identification. Several companies, including Thermo Fisher Scientific Inc. and QIAGEN N.V., were involved in product innovations.

Competitive Strategy: Enterprises led by market juggernauts frequently update their product portfolios with innovative and application-specific products to sustain current market competition. Moreover, a detailed competitive benchmarking of the players operating in the global clinical biomarkers market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Industry and Technology Overview

In 2021, the market was valued at $21,304.3 million, and it is expected to reach $54,294.0 million by 2032.

Global Clinical Biomarkers Market Industry Overview

In 2021, the global clinical biomarkers market was valued at $21,304.3 million, and it is expected to reach $54,294.0 million by 2032, growing at a CAGR of 8.73% during the forecast period 2022-2032. The growth in the global clinical biomarkers market is expected to be driven by the increasing demand for clinical biomarker products, increasing key player initiatives, and increasing prevalence of infectious diseases and various types of cancer globally.

Market Lifecycle Stage

Clinical biomarkers have been extensively preferred in the field of clinical medicine to offer individualized treatment options to patients. Biomarkers are crucial to the rational development of medical therapeutics and are involved in their use in in-vitro diagnostics purposes, particularly in the fields of chronic disease and nutrition. Companies such as Illumina, Inc., F. Hoffmann-La Roche Ltd Agilent Technologies, Inc., and Myriad Genetics, Inc., in the clinical biomarkers market are launching products, majorly focusing on indications for infectious diseases and cancer types such as breast cancer, ovarian cancer, lung cancer, and cervical cancer. Several companies, such as Thermo Fisher Scientific Inc., QIAGEN N.V., NeoGenomics Laboratories, and CENTOGENE N.V., are collaborating and partnering with the stakeholders to develop and expand technological expertise to offer potential products in the global clinical biomarkers market. Breast cancer is the most frequent tumor growth in women, and its incidence experienced innovation in systematic screening. The increasing incidence of breast cancer has led to an increase in demand for its diagnosis and treatment.

Impact

•   Increasing demand for clinical biomarkers products is anticipated to support the growth of the global clinical biomarkers market during the forecast period 2022-2032.
•   The market is expected to grow at a significant growth rate due to opportunities such as the expansion of biomarker discovery and increased research funding for executing research and development exercises.

Impact of COVID-19

The current global clinical biomarkers market comprises various applications such as translational research and clinical diagnostic. It has been noticed that there has been a reduction in the capacity or shutdowns of laboratories and other research institutions, which has led to reduced usage of various products and services related to research.

The government imposed various restrictions during COVID-19, such as travel bans, quarantines, curfews, business shutdowns, and closures. This led to an increased cost of COVID-19-related services. There have been many issues during the COVID-19 pandemic, such as operational failures, shipping issues, inaccurate demand forecasts, and other production issues.

Furthermore, the health and safety of employees were impacted as COVID-19 reduced the efficacy of employees' work potential. However, the market related to COVID-19 grew during the pandemic as customers were in need of testing services. The implementation of lockdown and travel restrictions amidst the pandemic shook the entire clinical biomarkers industry globally, leading to manufacturing difficulties and delays in clinical trials of biomarkers. The following section represents how the COVID-19 crisis is dismantling drug manufacturing along with the other industry sectors that rely on drug discovery and development, disease risk assessment, and others. The pandemic has impacted the clinical biomarkers market, resulting in fewer sales of the services. Furthermore, the sales of products and services would grow after COVID-19, resulting in better-operating outcomes. However, things have been better after the removal of various restrictions and lockdowns imposed by governments.

Market Segmentation:

Segmentation 1: by Offering
•    Product
•    Service

Based on offering, with respect to the overall market share, the service segment held the largest share, i.e., 55.41% of the global clinical biomarkers market in 2021. This trend is expected to continue during the forecast period 2022-2032, with the segment anticipated to hold a 52.88% share in 2032. The high share of the service segment is majorly due to the rising demand for clinical biomarkers services in oncology, the rising number of product launches and approval in recent years, and increasing emphasis on the adoption of clinical biomarkers technologies.

Segmentation 2: by Technology
•    Next-Generation Sequencing (NGS)
•    Polymerase Chain Reaction (PCR)
•    Immunohistochemistry (IHC)
•    Enzyme-Linked Immunosorbent Assay (ELISA)
•    Other Technologies

Based on technology, in 2021, global clinical biomarkers market was dominated by next-generation sequencing, with a massive market share of 31.28%. This trend is expected to continue during the forecast period 2022-2032, with the segment anticipated to hold a 34.34% share in 2032. This is primarily due to the growing cancer genomics research.

Segmentation 3: by Application
•    Clinical Diagnostic
•    Translational Research

Based on application, the translational research segment accounted for the largest share in 2021, holding a 53.03% market share. This trend is expected to continue during the forecast period 2022-2032, with the translational research segment expecting to have a 54.11% share of the market in 2032.

Segmentation 4: Clinical Area
•    Cancer Biomarker
•    Cardiac Biomarker
•    Neurological Biomarker
•    Infectious Disease Biomarker
•    Immunological Biomarker
•    Non-Invasive Prenatal Testing
•    Other Clinical Areas

Based on clinical area, the cancer biomarkers segment accounted for the largest share in 2021, holding a 42.04% market share. This trend is expected to continue during the forecast period 2022-2032. Increasing cancer cases across the globe will contribute significantly to the growth of this market.

Segmentation 5: by End User
•    Contract Research Organizations (CROs)
•    Research and Academic Laboratories
•    Biopharmaceutical and Biotech Companies
•    Diagnostic Centers
•    Other End Users

Based on end user, the contract research organizations (CROs) segment accounted for the largest share in 2021, holding a 35.69% market share. This trend is expected to continue during the forecast period 2022-2032.

Segmentation 6: by Region
•    North America
•    Europe
•    Asia-Pacific
•    Latin America
•    Rest-of-the-World

The North America region is expected to dominate the global clinical biomarkers market during the forecast period 2022-2032. North America has a high adoption rate of cancer genomics research. Backed by several healthcare companies working in the marketplace, the U.S. has the highest implementation of PCR, NGS, and other technologies.

Recent Developments in the Global Clinical Biomarkers Market

•    Acquisition in 2021: NeoGenomics Laboratories acquired Inivata. With this acquisition, the company strengthened its market position and expanded its footprint in the clinical biomarkers market.
•    Collaboration: In 2022, F. Hoffmann-La Roche Ltd collaborated with Nordic Bioscience to strengthen the development of biomarkers for chronic diseases.
•    Product Approval: In 2020, F. Hoffmann-La Roche Ltd received FDA approval for an assay to detect the HER2 biomarker in breast cancer.

Demand – Drivers and Limitations

Following are the demand drivers for the clinical biomarkers market:

•    Increasing Demand for Clinical Biomarker Products
•    Increasing Key Player Initiatives
•    Increasing Prevalence of Infectious Diseases and Various Types of Cancer Globally

The market is expected to face some limitations due to the following challenges:

•    Higher Price of Product/Service Hampering the Expansion in Low-Income countries
•    Complex Regulatory Frameworks Delaying the Approval of New Clinical Biomarkers Tests
•    Lack of Qualified Professionals

Table of Contents

Download this TOC

Get Free Sample

1.1    Product Definition
1.2    Inclusion and Exclusion

2.1    Key Questions Answered in the Report

3.1    Data Sources
         3.1.1    Primary Data Source
         3.1.2    Secondary Data Sources
                     3.1.2.1    Open Sources
3.2    Market Estimation Model
3.3    Criteria for Company Profiling

4.1    Introduction
4.2    Clinical Biomarkers Approaches in Precision Medicine
4.3    Market Size Potential for Clinical Biomarkers, 2021-2032
4.4    COVID-19 Impact on Global Clinical Biomarkers Market
         4.4.1    Impact on Market Size

5.1    Impact Analysis
5.2    Market Drivers
         5.2.1    Increasing Demand for Clinical Biomarker Products
         5.2.2    Rising Key Player Initiatives
         5.2.3    Increasing Prevalence of Infectious Diseases and Various Types of Cancer Globally
5.3    Market Challenges
         5.3.1    Higher Price of Product/Service Hampering the Expansion in Low-Income countries
         5.3.2    Complex Regulatory Frameworks Delaying the Approval of New Clinical Biomarkers Tests
         5.3.3    Lack of Qualified Professionals
5.4    Market Opportunities
         5.4.1    Technological Advancement in Biomarker Discovery
         5.4.2    Increased Research Funding for Executing Research and Development Exercise

6.1    Regulatory Framework
         6.1.1    Regulatory Framework in the U.S
         6.1.2    FDA Regulations
         6.1.3    Biomarker Qualification: Evidentiary Framework Guidance for Industry and FDA Staff
         6.1.4    Regulatory Framework in the U.S. for Medical Devices
         6.1.5    Legal Requirements and Framework in Europe
                     6.1.5.1    U.K.
                     6.1.5.2    Germany
         6.1.6    Legal Requirements and Framework in Asia-Pacific
                     6.1.6.1    China
                     6.1.6.2    Japan
                                    6.1.6.2.1    Pharmaceuticals and Medical Devices Agency (PMDA)
6.2    Patent Analysis

7.1    Corporate Strategies
         7.1.1    Acquisitions
         7.1.2    Synergistic Activities
         7.1.3    Funding and Business Expansions
7.2    Business Strategies
         7.2.1    Service/Product Launches
7.3    Supply Chain Analysis
7.4    Pricing Analysis
         7.4.1    Pricing Analysis by Product
         7.4.2    Pricing Analysis by Testing Services
7.5    Market Share Analysis (by Product Manufacturer)
7.6    Market Share Analysis (by Service Provider)
7.7    Growth-Share Analysis (by Product Manufacturer)
7.8    Growth-Share Analysis (by Service Provider)
7.9    Growth-Share Analysis (Application)
7.10    Growth-Share Analysis (End User)

8.1    Overview
8.2    Product
         8.2.1    Efficacy Biomarker
                     8.2.1.1    Diagnostic Biomarker
                     8.2.1.2    Predictive Biomarker
                     8.2.1.3    Prognostic Biomarker
         8.2.2    Safety Biomarker
         8.2.3    Validation Biomarker
8.3    Service
         8.3.1    Genomic Biomarker Service
         8.3.2    Tissue Biomarker Service
         8.3.3    Cell Service
         8.3.4    Proteomics Service

9.1    Overview
9.2    Next-Generation Sequencing (NGS)
9.3    Polymerase Chain Reaction (PCR)
9.4    Immunohistochemistry (IHC)
9.5    Enzyme-Linked Immunosorbent Assay (ELISA)
9.6    Other Technologies

10.1    Overview
10.2    Cancer Biomarker
           10.2.1    Breast Cancer Biomarker
           10.2.2    Lung Cancer Biomarker
           10.2.3    Colorectal Cancer Biomarker
           10.2.4    Prostate Cancer Biomarker
           10.2.5    Other
10.3    Cardiac Biomarker
10.4    Neurological Biomarker
10.5    Infectious Disease Biomarker
10.6    Non-Invasive Prenatal Testing
10.7    Immunological Biomarker
10.8    Other Clinical Areas

11.1    Overview
           11.1.1    Translational Research
           11.1.2    Clinical Diagnostic

12.1    Overview
           12.1.1    Contract Research Organizations (CROs)
           12.1.2    Research and Academic Laboratories
           12.1.3    Diagnostic Centers
           12.1.4    Biopharmaceutical and Biotech Companies
           12.1.5    Other End Users

13.1    Overview
13.2    North America
           13.2.1    U.S.
           13.2.2    Canada
13.3    Europe
           13.3.1    Germany
           13.3.2    France
           13.3.3    U.K.
           13.3.4    Italy
           13.3.5    Spain
           13.3.6    Rest-of-Europe
13.4    Asia-Pacific
           13.4.1    China
           13.4.2    India
           13.4.3    Japan
           13.4.4    South Korea
           13.4.5    Australia
           13.4.6    Rest-of-Asia-Pacific
13.5    Latin America
           13.5.1    Brazil
           13.5.2    Mexico
           13.5.3    Rest-of-Latin America
13.6    Rest-of-the-World

14.1    Overview
14.2    Abbott.
           14.2.1    Company Overview
           14.2.2    Role of Abbott. in the Global Clinical Biomarkers Market
           14.2.3    Key Competitors of the Company
           14.2.4    Corporate Strategies
           14.2.5    Business Strategies
           14.2.6    Financials
           14.2.7    Key Insights about the Financial Health of the Company
           14.2.8    Analyst’s Perspective
14.3    Agilent Technologies, Inc.
           14.3.1    Company Overview
           14.3.2    Role of Agilent Technologies, Inc. in the Global Clinical Biomarkers Market
           14.3.3    Key Competitors of the Company
           14.3.4    Corporate Strategies
           14.3.5    Financials
           14.3.6    Key Insights about the Financial Health of the Company
           14.3.7    Analyst’s Perspective
14.4    Bio-Rad Laboratories, Inc.
           14.4.1    Company Overview
           14.4.2    Role of Bio-Rad Laboratories, Inc. in the Global Clinical Biomarkers Market
           14.4.3    Key Competitors of the Company
           14.4.4    Financials
           14.4.5    Key Insights about the Financial Health of the Company
           14.4.6    Analyst’s Perspective
14.5    Illumina, Inc.
           14.5.1    Company Overview
           14.5.2    Role of Illumina, Inc. in the Global Clinical Biomarkers Market
           14.5.3    Key Competitors of the Company
           14.5.1    Corporate Strategies
           14.5.2    Financials
           14.5.3    Key Insights about the Financial Health of the Company
           14.5.4    Analyst’s Perspective
14.6    PerkinElmer Inc.
           14.6.1    Company Overview
           14.6.2    Role of PerkinElmer Inc. in the Global Clinical Biomarkers Market
           14.6.3    Key Competitors of the Company
           14.6.4    Financials
           14.6.5    Key Insights about the Financial Health of the Company
           14.6.6    Analyst’s Perspective
14.7    QIAGEN N.V.
           14.7.1    Company Overview
           14.7.2    Role of QIAGEN N.V. in the Global Clinical Biomarkers Market
           14.7.3    Key Competitors of the Company
           14.7.4    Key Customers of the Company
           14.7.5    Corporate Strategies
           14.7.6    Business Strategies
           14.7.7    Financials
           14.7.8    Key Insights about the Financial Health of the Company
           14.7.9    Analyst’s Perspective
14.8    Thermo Fisher Scientific Inc.
           14.8.1    Company Overview
           14.8.2    Role of Thermo Fisher Scientific Inc. in the Global Clinical Biomarkers Market
           14.8.3    Key Competitors of the Company
           14.8.4    Business Strategies
           14.8.5    Corporate Strategies
           14.8.6    Financials
           14.8.7    Key Insights about the Financial Health of the Company
           14.8.8    Analyst’s Perspective
14.9    NeoGenomics Laboratories
           14.9.1    Company Overview
           14.9.2    Role of NeoGenomics Laboratories in the Global Clinical Biomarkers Market
           14.9.3    Key Competitors of the Company
           14.9.4    Key Customers of the Company
           14.9.5    Business Strategies
           14.9.6    Financials
           14.9.7    Key Insights about the Financial Health of the Company
           14.9.8    Analyst’s Perspective
14.10    Charles River Laboratories
             14.10.1    Company Overview
             14.10.2    Role of Charles River Laboratories in the Global Clinical Biomarkers Market
             14.10.3    Financials
             14.10.4    Analyst’s Perspective
14.11    F. Hoffmann-La Roche Ltd
             14.11.1    Company Overview
             14.11.2    Role of F. Hoffmann-La Roche Ltd in the Global Clinical Biomarkers Market
             14.11.3    Key Competitors of the Company
             14.11.4    Business Strategies
             14.11.5    Corporate Strategies
             14.11.6    Financials
             14.11.7    Key Insights about the Financial Health of the Company
             14.11.8    Analyst’s Perspective
14.12    Quest Diagnostics Incorporated
             14.12.1    Company Overview
             14.12.2    Role of Quest Diagnostics Incorporated in the Global Clinical Biomarkers Market
             14.12.3    Key Competitors of the Company
             14.12.4    Financials
             14.12.5    Analyst Perspective
14.13    Enzo Biochem Inc.
             14.13.1    Company Overview
             14.13.2    Role of Enzo Biochem Inc. in the Global Clinical Biomarkers Market
             14.13.3    Key Competitors of the Company
             14.13.4    Financials
             14.13.5    Key Insights about the Financial Health of the Company
             14.13.6    Analyst’s Perspective
14.14    ALCEN
             14.14.1    Company Overview
             14.14.2    Role of ALCEN in Global Clinical Biomarkers Market
             14.14.3    Analyst’s Perspective
14.15    Myriad Genetics, Inc.
             14.15.1    Company Overview
             14.15.2    Role of Myriad Genetics, Inc. in the Global Clinical Biomarkers Market
             14.15.3    Corporate Strategies
             14.15.4    Financials
             14.15.5    Key Insights about the Financial Health of the Company
             14.15.6    Analyst’s Perspective
14.16    CENTOGENE N.V.
             14.16.1    Company Overview
             14.16.2    Role of CENTOGENE N.V. in the Global Clinical Biomarkers Market
             14.16.3    Business Strategies
             14.16.4    Financials
             14.16.5    Key Insights about the Financial Health of the Company
             14.16.6    Analyst’s Perspective
14.17    bioMérieux S.A.
             14.17.1    Company Overview
             14.17.2    Role of bioMérieux S.A. in the Global Clinical Biomarkers Market
             14.17.3    Corporate Strategies
             14.17.4    Business Strategies
             14.17.5    Financials
             14.17.6    Analyst’s Perspective
14.18    Arsenal Capital Partners
             14.18.1    Company Overview
             14.18.2    Role of Arsenal Capital Partners in the Global Clinical Biomarkers Market
             14.18.3    Business Strategies
             14.18.4    Analyst’s Perspective
14.19    Novogene Co., Ltd.
             14.19.1    Company Overview
             14.19.2    Role of Novogene Co., Ltd. in the Global Clinical Biomarkers Market
             14.19.3    Analyst’s Perspective
14.20    Q2 Solutions
             14.20.1    Company Overview
             14.20.2    Role of Q2 Solutions in the Global Clinical Biomarkers Market
             14.20.3    Business Strategies
             14.20.4    Analyst’s Perspective
14.21    Caris Life Sciences
             14.21.1    Company Overview
             14.21.2    Role of Caris Life Sciences in the Global Clinical Biomarkers Market
             14.21.3    Analyst’s Perspective
14.22    Broad Institute
             14.22.1    Company Overview
             14.22.2    Role of Broad Institute in the Global Clinical Biomarkers Market    
             14.22.3    Analyst’s Perspective
14.23    Personalis Inc.
             14.23.1    Company Overview
             14.23.2    Role of Personalis Inc. in the Global Clinical Biomarkers Market    
             14.23.3    Key Competitors of the Company
             14.23.4    Key Customers of the Company
             14.23.5    Business Strategies
             14.23.6    Corporate Strategies
             14.23.7    Financials
             14.23.8    Key Insights about the Financial Health of the Company
             14.23.9    Analyst’s Perspective
14.24    Azenta Life Sciences
             14.24.1    Company Overview
             14.24.2    Role of Azenta Life Sciences in the Global Clinical Biomarkers Market
             14.24.3    Business Strategies
             14.24.4    Analyst’s Perspectives
14.25    Discovery Life Sciences(DLS)
             14.25.1    Company Overview
             14.25.2    Role of Discovery Life Sciences in the Global Clinical Biomarkers Market
             14.25.3    Key Partners
             14.25.4    Business Strategies
             14.25.5    Analyst’s Perspective
14.26    BGI
             14.26.1    Company Overview
             14.26.2    Role of BGI in Global Clinical Biomarkers Market
             14.26.3    Corporate Strategies
             14.26.4    Analyst’s Perspective
14.27    Eurofins Scientific
             14.27.1    Company Overview
             14.27.2    Role of Eurofins Scientific in the Global Clinical Biomarkers Market
             14.27.3    Key Competitors of the Company
             14.27.4    Corporate Strategies
             14.27.5    Financials
             14.27.6    Analyst’s Perspective
14.28    Becton, Dickinson and Company
             14.28.1    Company Overview
             14.28.2    Role of Becton, Dickinson and Company in the Global Clinical Biomarkers Market
             14.28.3    Financials
             14.28.4    Key Insights about the Financial Health of the Company
             14.28.5    Analyst’s Perspective

Table 1:    COVID-19 Impact on Global Clinical Biomarkers Market
Table 2:    Key Player Initiatives
Table 3:    Pricing List of Product/Service
Table 4:    List of Product/Service and its Technology
Table 5:    Global Clinical Biomarkers Market: Key Players Patent Portfolio
Table 6:    Example of Efficacy Biomarker
Table 7:    Examples of Diagnostic Biomarker
Table 8:    Examples of Prognostic Biomarker
Table 9:    Examples of Safety Biomarker
Table 10:    Example of Clinical Biomarker Service
Table 11:    Next-Generation Sequencing-Based Clinical Biomarker Products
Table 12:    Polymerase Chain Reaction-Based Clinical Biomarker Products
Table 13:    Immunohistochemistry (IHC)-Based Clinical Biomarker Products
Table 14:    ELISA-Based Clinical Biomarker Products
Table 15:    Companies Offering Other Technologies-Based Products
Table 16:    Example of Cancer Biomarker
Table 17:    Example of  Cardiac Biomarker
Table 18:    Example of  Neurological Biomarker
Table 19:    Examples of Infectious Disease Biomarker
Table 20:    Estimated Cancer Deaths in California, 2022

Figure 1:    Global Clinical Biomarkers Market Dynamics
Figure 2:    Global Clinical Biomarkers Market (by Offering), $Million, 2021 and 2032
Figure 3:    Global Clinical Biomarkers Market (by Application), $Million, 2021 and 2032
Figure 4:    Global Clinical Biomarkers Market (by Technology), $Million, 2021 and 2032
Figure 5:    Global Clinical Biomarkers Market (by Clinical Area), $Million, 2021 and 2032
Figure 6:    Global Clinical Biomarkers Market (by End User), $Million, 2021 and 2032
Figure 7:    Global Clinical Biomarkers Market (by Region), $Million, 2021
Figure 8:    Global Clinical Biomarkers Market Research Methodology
Figure 9:    Primary Research Methodology
Figure 10:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 11:    Top-Down Approach (Segment-Wise Analysis)
Figure 12:    Biomarkers Used in Various Clinical Areas
Figure 13:    Leading Segments of the Global Clinical Biomarkers Market, 2021 and 2032
Figure 14:    Global Clinical Biomarkers Market, $Million, 2021-2032
Figure 15:    Pre-COVID-19 and Post-COVID-19 Scenario of Global Clinical Biomarkers Market, $Million, 2019-2025
Figure 16:    Impact of COVID-19 on Clinical Biomarkers Market
Figure 17:    Global Clinical Biomarkers Market Dynamics
Figure 18:    Percentage of People Reporting Chronic Lower Respiratory Diseases in Europe Region, 2019
Figure 19:    Cancer Cases in U.S., 2021
Figure 20:    NIH Funding, 2019-2022
Figure 21:    Responsibilities of the National Medical Products Administration (NMPA)
Figure 22:    Synergistic Activities Share (by Company), January 2019-July 2022
Figure 23:    Funding and Business Expansions (by Company), January 2019-July 2022
Figure 24:    Service/Product Launches (by Key Companies), January 2019-July 2022
Figure 25:    Clinical Biomarkers Supply Chain Analysis
Figure 26:    Global Clinical Biomarkers Market Share Analysis (by Product Manufacturer), 2020 and 2021
Figure 27:    Global Clinical Biomarkers Market Share Analysis (by Service Provider), 2020 and 2021
Figure 28:    Growth-Share Analysis for Global Clinical Biomarkers Market (by Product Manufacturer)
Figure 29:    Growth-Share Analysis for Global Clinical Biomarkers Market (by Service Provider)
Figure 30:    Growth Share Analysis for Global Clinical Biomarkers Market (by Application), 2021-2032
Figure 31:    Growth Share Analysis for Global Clinical Biomarkers Market (by End User), 2021-2032
Figure 32:    Global Clinical Biomarkers Market (by Offering)
Figure 33:    Share of Global Clinical Biomarkers Market (by Offering), $Million, 2021 and 2032
Figure 34:    Share of Global Clinical Biomarkers Market (by Product), $Million, 2021 and 2032
Figure 35:    Global Clinical Biomarkers Market (Product), $Million, 2021-2032
Figure 36:    Global Clinical Biomarkers Market (Efficacy Biomarker), $Million, 2021-2032
Figure 37:    Global Clinical Biomarkers Market (Diagnostic Biomarker), $Million, 2021-2032
Figure 38:    Role and Example of Predictive Biomarker
Figure 39:    Global Clinical Biomarkers Market (Predictive Biomarker), $Million, 2021-2032
Figure 40:    Global Clinical Biomarkers Market (Prognostic Biomarker), $Million, 2021-2032
Figure 41:    Global Clinical Biomarkers Market (Safety Biomarker), $Million, 2021-2032
Figure 42:    Global Clinical Biomarkers Market (Validation Biomarker), $Million, 2021-2032
Figure 43:    Share of Global Clinical Biomarkers Market (by Service), $Million, 2021 and 2032
Figure 44:    Global Clinical Biomarkers Market (Service), $Million, 2021-2032
Figure 45:    Global Clinical Biomarkers Market (Genomic Biomarker Service), $Million, 2021-2032
Figure 46:    Global Clinical Biomarkers Market (Tissue Biomarker Service), $Million, 2021-2032
Figure 47:    Global Clinical Biomarkers Market (Cell Service), $Million, 2021-2032
Figure 48:    Global Clinical Biomarkers Market (Proteomics Service), $Million, 2021-2032
Figure 49:    Global Clinical Biomarkers Market (by Technology)
Figure 50:    Global Clinical Biomarkers Market (by Technology), $Million, 2021 and 2032
Figure 51:    Benefits of NGS for Clinical Diagnostics and Biomarker Testing in Oncology
Figure 52:    Global Clinical Biomarkers market (Next-Generation Sequencing), $Million, 2021-2032
Figure 53:    Global Next-Generation Sequencing Market (Service), $Million, 2021-2032
Figure 54:    Application of PCR
Figure 55:    Global Clinical Biomarkers Market (Polymerase Chain Reaction), $Million, 2021-2032
Figure 56:    Global Polymerase Chain Reaction Market (Service), $Million, 2021-2032
Figure 57:    Global Clinical Biomarkers Market (Immunohistochemistry (IHC)), $Million, 2021-2032
Figure 58:    Global Immunohistochemistry (IHC) Market (Service), $Million, 2021-2032
Figure 59:    Global Clinical Biomarkers Market Enzyme-Linked Immunosorbent Assay (ELISA)), $Million, 2021-2032
Figure 60:    Global Enzyme-Linked Immunosorbent assay (ELISA) Market (Service), $Million, 2021-2032
Figure 61:    Global Clinical Biomarkers Market (Other Technologies), $Million, 2021-2032
Figure 62:    Global Other Technology Market (Service), $Million, 2021-2032
Figure 63:    Global Clinical Biomarkers Market (by Clinical Area)
Figure 64:    Global Clinical Biomarkers Market (by Clinical Area), $Million, 2021 and 2032
Figure 65:    Global Clinical Biomarkers Market (Cancer Biomarker), $Million, 2021-2032
Figure 66:    Global Clinical Biomarkers Market (Breast Cancer Biomarker), $Million, 2021-2032
Figure 67:    Global Clinical Biomarkers Market (Lung Cancer Biomarker), $Million, 2021-2032
Figure 68:    Global Clinical Biomarkers Market (Colorectal Cancer Biomarker), $Million, 2021-2032
Figure 69:    Global Clinical Biomarkers Market (Prostate Cancer Biomarker), $Million, 2021-2032
Figure 70:    Global Clinical Biomarkers Market (Other), $Million, 2021-2032
Figure 71:    Global Clinical Biomarkers Market (Cardiac Biomarker), $Million, 2021-2032
Figure 72:    Global Clinical Biomarkers Market (Neurological Biomarker), $Million, 2021-2032
Figure 73:    Global Clinical Biomarkers Market (Infectious Disease Biomarker), $Million, 2021-2032
Figure 74:    Global Clinical Biomarkers Market Non-Invasive Prenatal Testing (NIPT)), $Million, 2021-2032
Figure 75:    Global Clinical Biomarkers Market (Immunological Biomarker), $Million, 2021-2032
Figure 76:    Global Clinical Biomarkers market (Other Clinical Areas), $Million, 2021-2032
Figure 77:    Global Clinical Biomarkers Market (by Application)
Figure 78:    Global Clinical Biomarkers Market (by Application), 2021 vs. 2032
Figure 79:    Global Clinical Biomarkers Market (Translational Research), $Million, 2021-2032
Figure 80:    Global Clinical Biomarkers Market (Clinical Diagnostic), $Million, 2021-2032
Figure 81:    Global Clinical Biomarkers Market (by End User), 2021 vs. 2032
Figure 82:    Global Clinical Biomarkers Market (Contract Research Organizations (CROs)), $Million, 2021-2032
Figure 83:    Global Clinical Biomarkers Market (Research and Academic Laboratories), $Million, 2021-2032
Figure 84:    Global Clinical Biomarkers Market (Diagnostic Centers), $Million, 2021-2032
Figure 85:    Global Clinical Biomarkers Market (Biopharmaceutical and Biotech Companies), $Million, 2021-2032
Figure 86:    Global Clinical Biomarkers Market (Other End Users), $Million, 2021-2032
Figure 87:    Global Clinical Biomarkers Market Snapshot (by Region), $Million, 2021-2032
Figure 88:    Global Clinical Biomarkers Market (by Region), $Million, 2021-2032
Figure 89:    Global Clinical Biomarkers Market (by Region), $Million, 2021 and 2032
Figure 90:    North America Clinical Biomarkers Market, $Million, 2021-2032
Figure 91:    North America: Market Dynamics
Figure 92:    North America Clinical Biomarkers Market (by Country), $Million, 2021-2032
Figure 93:    U.S. Clinical Biomarkers Market, $Million, 2021-2032
Figure 94:    Canada Clinical Biomarkers Market, $Million, 2021-2032
Figure 95:    Europe Clinical Biomarkers Market, $Million, 2021-2032
Figure 96:    Europe: Market Dynamics
Figure 97:    Europe Clinical Biomarkers Market (by Country), $Million, 2021-2032
Figure 98:    Germany Clinical Biomarkers Market, $Million, 2021-2032
Figure 99:    Share of Cancer Cases in Germany, 2020
Figure 100:    France Clinical Biomarkers Market, $Million, 2021-2032
Figure 101:    U.K. Clinical Biomarkers Market, $Million, 2021-2032
Figure 102:    Italy Clinical Biomarkers Market, $Million, 2021-2032
Figure 103:    Spain Clinical Biomarkers Market, $Million, 2021-2032
Figure 104:    Rest-of-Europe Clinical Biomarkers Market, $Million, 2021-2032
Figure 105:    Asia-Pacific Clinical Biomarkers Market, $Million, 2021-2032
Figure 106:    Asia-Pacific Clinical Biomarkers Market (by Country), $Million, 2021-2032
Figure 107:    Asia-Pacific: Market Dynamics
Figure 108:    China Clinical Biomarkers Market, $Million, 2021-2032
Figure 109:    India Clinical Biomarkers Market, $Million, 2021-2032
Figure 110:    Japan Clinical Biomarkers Market, $Million, 2021-2032
Figure 111:    South Korea Clinical Biomarkers Market, $Million, 2021-2032
Figure 112:    Australia Clinical Biomarkers Market, $Million, 2021-2032
Figure 113:    Rest-of-Asia-Pacific Clinical Biomarkers Market, $Million, 2021-2032
Figure 114:    Latin America Clinical Biomarkers Market, $Million, 2021-2032
Figure 115:    Latin America: Market Dynamics
Figure 116:    Latin America Clinical Biomarkers Market (by Country), $Million, 2021-2032
Figure 117:    Brazil Clinical Biomarkers Market, $Million, 2021-2032
Figure 118:    Mexico Clinical Biomarkers Market, $Million, 2021-2032
Figure 119:    Rest-of-Latin America Clinical Biomarkers Market, $Million, 2021-2032
Figure 120:    Rest-of-the-World) Clinical Biomarkers Market, $Million, 2021-2032
Figure 121:    Total Number of Companies Profiled
Figure 122:    Abbott.: Product Portfolio
Figure 123:    Abbott.: Overall Financials, $Million, 2019-2021
Figure 124:    Abbott.: Revenue (by Segment), $Million, 2019-2021
Figure 125:    Abbott.: Revenue (by Region), $Million, 2019-2021
Figure 126:    Abbott.: R&D Expenditure, $Million, 2019-2021
Figure 127:    Agilent Technologies, Inc.: Product Portfolio
Figure 128:    Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021
Figure 129:    Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 130:    Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 131:    Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 132:    Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 133:    Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 134:    Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 135:    Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 136:    Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 137:    Illumina, Inc.: Product Portfolio
Figure 138:    Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 139:    Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 140:    Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 141:    Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 142:    PerkinElmer Inc.: Product Portfolio
Figure 143:    PerkinElmer Inc.: Overall Financials, $Million, 2019-2021
Figure 144:    PerkinElmer Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 145:    PerkinElmer Inc.: Revenue (by Region), $Million, 2019-2021
Figure 146:    PerkinElmer Inc.: R&D Expenditure, $Million, 2019-2021
Figure 147:    QIAGEN N.V.: Product Portfolio
Figure 148:    QIAGEN N.V.: Overall Financials, $Million, 2019-2021
Figure 149:    QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021
Figure 150:    QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021
Figure 151:    QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
Figure 152:    Thermo Fisher Scientific Inc.: Product Portfolio
Figure 153:    Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
Figure 154:    Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 155:    Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
Figure 156:    Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
Figure 157:    NeoGenomics Laboratories: Service Portfolio
Figure 158:    NeoGenomics Laboratories: Overall Financials, $Million 2019-2021
Figure 159:    NeoGenomics Laboratories: Revenue (by Segment), 2019-2021
Figure 160:    NeoGenomics Laboratories: R&D Expenditure, 2019-2021
Figure 161:    Charles River Laboratories: Service Portfolio
Figure 162:    Charles River Laboratories: Overall Financials, $Million, 2019-2021
Figure 163:    Charles River Laboratories: Revenue (by Segment), $Million, 2019-2021
Figure 164:    Charles River Laboratories.: Revenue (by Region), $Million, 2019-2021
Figure 165:    F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 166:    F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
Figure 167:    F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
Figure 168:    F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021
Figure 169:    F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
Figure 170:    Quest Diagnostics Incorporated, Inc.: Service Portfolio
Figure 171:    Quest Diagnostics Incorporated: Overall Financials, $Million, 2019-2021
Figure 172:    Quest Diagnostics Incorporated.: Revenue (by Segment), $Million, 2019-2021
Figure 173:    Enzo Biochem Inc.: Product Portfolio
Figure 174:    Enzo Biochem Inc.: Overall Financials, $Million, 2019-2021
Figure 175:    Enzo Biochem Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 176:    Enzo Biochem Inc.: Revenue (by Region), $Million, 2019-2021
Figure 177:    Enzo Biochem Inc.: R&D Expenditure, 2019-2021
Figure 178:    ALCEN.: Service Portfolio
Figure 179:    Myriad Genetics, Inc.: Service Portfolio
Figure 180:    Myriad Genetics, Inc.: Overall Financials, $Million, 2019-2021
Figure 181:    Myriad Genetics, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 182:    Myriad Genetics, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 183:    CENTOGENE N.V.: Service Portfolio
Figure 184:    CENTOGENE N.V.: Overall Financials, $Million, 2019-2021
Figure 185:    CENTOGENE N.V.: Revenue (by Segment), $Million, 2019-2021
Figure 186:    CENTOGENE N.V.: Revenue (by Region), $Million, 2019-2021
Figure 187:    CENTOGENE N.V.: R&D Expenditure, $Million, 2019-2021
Figure 188:    bioMérieux S.A.: Product Portfolio
Figure 189:    bioMérieux S.A.: Overall Financials, $Million, 2019-2021
Figure 190:    bioMérieux S.A.: Revenue (by Segment), $Million, 2019-2021
Figure 191:    bioMérieux S.A.: Revenue (by Region), $Million, 2019-2021
Figure 192:    Arsenal Capital Partners: Services Portfolio
Figure 193:    Novogene Co., Ltd.: Service Portfolio
Figure 194:    Q2 Solutions: Service Portfolio
Figure 195:    Caris Life Sciences: Service Portfolio
Figure 196:    Broad Institute: Service Portfolio
Figure 197:    Personalis Inc.: Service Portfolio
Figure 198:    Personalis Inc.: Overall Financials, $Million, 2019-2021
Figure 199:    Personalis Inc.: R&D Expenditure, $Million, 2019-2021
Figure 200:    Azenta Life Sciences: Service Portfolio
Figure 201:    Discovery Life Sciences: Service Portfolio
Figure 202:    BGI: Service Portfolio
Figure 203:    Eurofins Scientific: Service Portfolio
Figure 204:    Eurofins Scientific: Overall Financials, $Million, 2019-2021
Figure 205:    Eurofins Scientific: Revenue (by Region), $Million, 2019-2021
Figure 206:    Becton, Dickinson and Company: Product Portfolio
Figure 207:    Becton, Dickinson and Company: Overall Financials, $Million, 2019-2021
Figure 208:    Becton, Dickinson and Company: Revenue (by Region), $Million, 2019-2021
Figure 209:    Becton, Dickinson and Company: R&D Expenditure, $Million, 2019-2021

Market Report Coverage

Clinical Biomarkers Market

Base Year

2021

Market Size in 2021

$21,304.3 Million

Forecast Period

2022-2032

Value Projection and Estimation by 2032

$54,294.0 Million

CAGR During Forecast Period

8.73%

Number of Tables

20

Number of Pages

254

Number of Figures

209

 

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

•    Abbott.
•    Agilent Technologies, Inc.
•    Bio-Rad Laboratories, Inc.
•    Illumina, Inc.
•    PerkinElmer Inc.
•    QIAGEN N.V.
•    Thermo Fisher Scientific Inc.
•    NeoGenomics Laboratories
•    Charles River Laboratories
•    F. Hoffmann-La Roche Ltd
•    Quest Diagnostics Incorporated
•    Enzo Biochem Inc.
•    ALCEN
•    Myriad Genetics, Inc.
•    CENTOGENE N.V.
•    bioMérieux S.A.
•    Arsenal Capital Partners
•    Novogene Co., Ltd.
•    Q2 Solutions
•    Caris Life Sciences
•    Broad Institute
•    Personalis Inc.
•    Azenta Life Sciences
•    Discovery Life Sciences(DLS)
•    BGI
•    Eurofins Scientific
•    Becton, Dickinson and Company

How can this report add value to an organization?

Product/Innovation Strategy:  Product launches and upgrades in the clinical biomarkers industry are aimed at advancing the overall technologies in the market to ensure efficient detection of various applications such as forensic and paternity identification. Several companies, including Thermo Fisher Scientific Inc. and QIAGEN N.V., were involved in product innovations.

Competitive Strategy: Enterprises led by market juggernauts frequently update their product portfolios with innovative and application-specific products to sustain current market competition. Moreover, a detailed competitive benchmarking of the players operating in the global clinical biomarkers market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Industry and Technology Overview

Global Clinical Biomarkers Market Industry Overview

In 2021, the global clinical biomarkers market was valued at $21,304.3 million, and it is expected to reach $54,294.0 million by 2032, growing at a CAGR of 8.73% during the forecast period 2022-2032. The growth in the global clinical biomarkers market is expected to be driven by the increasing demand for clinical biomarker products, increasing key player initiatives, and increasing prevalence of infectious diseases and various types of cancer globally.

Market Lifecycle Stage

Clinical biomarkers have been extensively preferred in the field of clinical medicine to offer individualized treatment options to patients. Biomarkers are crucial to the rational development of medical therapeutics and are involved in their use in in-vitro diagnostics purposes, particularly in the fields of chronic disease and nutrition. Companies such as Illumina, Inc., F. Hoffmann-La Roche Ltd Agilent Technologies, Inc., and Myriad Genetics, Inc., in the clinical biomarkers market are launching products, majorly focusing on indications for infectious diseases and cancer types such as breast cancer, ovarian cancer, lung cancer, and cervical cancer. Several companies, such as Thermo Fisher Scientific Inc., QIAGEN N.V., NeoGenomics Laboratories, and CENTOGENE N.V., are collaborating and partnering with the stakeholders to develop and expand technological expertise to offer potential products in the global clinical biomarkers market. Breast cancer is the most frequent tumor growth in women, and its incidence experienced innovation in systematic screening. The increasing incidence of breast cancer has led to an increase in demand for its diagnosis and treatment.

Impact

•   Increasing demand for clinical biomarkers products is anticipated to support the growth of the global clinical biomarkers market during the forecast period 2022-2032.
•   The market is expected to grow at a significant growth rate due to opportunities such as the expansion of biomarker discovery and increased research funding for executing research and development exercises.

Impact of COVID-19

The current global clinical biomarkers market comprises various applications such as translational research and clinical diagnostic. It has been noticed that there has been a reduction in the capacity or shutdowns of laboratories and other research institutions, which has led to reduced usage of various products and services related to research.

The government imposed various restrictions during COVID-19, such as travel bans, quarantines, curfews, business shutdowns, and closures. This led to an increased cost of COVID-19-related services. There have been many issues during the COVID-19 pandemic, such as operational failures, shipping issues, inaccurate demand forecasts, and other production issues.

Furthermore, the health and safety of employees were impacted as COVID-19 reduced the efficacy of employees' work potential. However, the market related to COVID-19 grew during the pandemic as customers were in need of testing services. The implementation of lockdown and travel restrictions amidst the pandemic shook the entire clinical biomarkers industry globally, leading to manufacturing difficulties and delays in clinical trials of biomarkers. The following section represents how the COVID-19 crisis is dismantling drug manufacturing along with the other industry sectors that rely on drug discovery and development, disease risk assessment, and others. The pandemic has impacted the clinical biomarkers market, resulting in fewer sales of the services. Furthermore, the sales of products and services would grow after COVID-19, resulting in better-operating outcomes. However, things have been better after the removal of various restrictions and lockdowns imposed by governments.

Market Segmentation:

Segmentation 1: by Offering
•    Product
•    Service

Based on offering, with respect to the overall market share, the service segment held the largest share, i.e., 55.41% of the global clinical biomarkers market in 2021. This trend is expected to continue during the forecast period 2022-2032, with the segment anticipated to hold a 52.88% share in 2032. The high share of the service segment is majorly due to the rising demand for clinical biomarkers services in oncology, the rising number of product launches and approval in recent years, and increasing emphasis on the adoption of clinical biomarkers technologies.

Segmentation 2: by Technology
•    Next-Generation Sequencing (NGS)
•    Polymerase Chain Reaction (PCR)
•    Immunohistochemistry (IHC)
•    Enzyme-Linked Immunosorbent Assay (ELISA)
•    Other Technologies

Based on technology, in 2021, global clinical biomarkers market was dominated by next-generation sequencing, with a massive market share of 31.28%. This trend is expected to continue during the forecast period 2022-2032, with the segment anticipated to hold a 34.34% share in 2032. This is primarily due to the growing cancer genomics research.

Segmentation 3: by Application
•    Clinical Diagnostic
•    Translational Research

Based on application, the translational research segment accounted for the largest share in 2021, holding a 53.03% market share. This trend is expected to continue during the forecast period 2022-2032, with the translational research segment expecting to have a 54.11% share of the market in 2032.

Segmentation 4: Clinical Area
•    Cancer Biomarker
•    Cardiac Biomarker
•    Neurological Biomarker
•    Infectious Disease Biomarker
•    Immunological Biomarker
•    Non-Invasive Prenatal Testing
•    Other Clinical Areas

Based on clinical area, the cancer biomarkers segment accounted for the largest share in 2021, holding a 42.04% market share. This trend is expected to continue during the forecast period 2022-2032. Increasing cancer cases across the globe will contribute significantly to the growth of this market.

Segmentation 5: by End User
•    Contract Research Organizations (CROs)
•    Research and Academic Laboratories
•    Biopharmaceutical and Biotech Companies
•    Diagnostic Centers
•    Other End Users

Based on end user, the contract research organizations (CROs) segment accounted for the largest share in 2021, holding a 35.69% market share. This trend is expected to continue during the forecast period 2022-2032.

Segmentation 6: by Region
•    North America
•    Europe
•    Asia-Pacific
•    Latin America
•    Rest-of-the-World

The North America region is expected to dominate the global clinical biomarkers market during the forecast period 2022-2032. North America has a high adoption rate of cancer genomics research. Backed by several healthcare companies working in the marketplace, the U.S. has the highest implementation of PCR, NGS, and other technologies.

Recent Developments in the Global Clinical Biomarkers Market

•    Acquisition in 2021: NeoGenomics Laboratories acquired Inivata. With this acquisition, the company strengthened its market position and expanded its footprint in the clinical biomarkers market.
•    Collaboration: In 2022, F. Hoffmann-La Roche Ltd collaborated with Nordic Bioscience to strengthen the development of biomarkers for chronic diseases.
•    Product Approval: In 2020, F. Hoffmann-La Roche Ltd received FDA approval for an assay to detect the HER2 biomarker in breast cancer.

Demand – Drivers and Limitations

Following are the demand drivers for the clinical biomarkers market:

•    Increasing Demand for Clinical Biomarker Products
•    Increasing Key Player Initiatives
•    Increasing Prevalence of Infectious Diseases and Various Types of Cancer Globally

The market is expected to face some limitations due to the following challenges:

•    Higher Price of Product/Service Hampering the Expansion in Low-Income countries
•    Complex Regulatory Frameworks Delaying the Approval of New Clinical Biomarkers Tests
•    Lack of Qualified Professionals

You may also like

Published Year:2022

Europe Infectious Disease Diagnostics Market - Country-Wise Analysis: Focus on Product, Testing Loca

The Europe infectious disease diagnostics market is projected to reach $7,900.4 million by...

Published Year:2021

Molecular Diagnostics Market - A Global and Regional Analysis: Focus on Product, Testing Location, A

The global molecular diagnostics market is projected to reach $24,228.0 million by 2031 from...

Clinical Biomarkers - A Global and Regional Analysis

Focus on Offering, Clinical Area, Technology, Application, End User, and Region - Analysis and Forecast, 2022-2032